General Partner, Frazier Healthcare Partners
Dan is a General Partner on the Frazier Life Sciences team and has been involved with investing in and building many of Frazier’s biopharmaceutical portfolio companies over the past 13 years. Dan has been a co-founder and board member of Lengo Therapeutics (acquired by Blueprint Medicines), Arcutis (NASDAQ: ARQT), Sudo Bio, Inipharm, and Radionetics Oncology. He has also led Frazier’s investments in Tarsus Pharmaceuticals (NASDAQ: TARS), Sierra Oncology (acquired by GSK), Semnur Pharmaceuticals (acquired by Scilex), and Hummingbird Bioscience. Prior to Frazier, Dan was a management consultant in McKinsey & Company’s healthcare practice. He holds a Ph.D. in Biomedical Engineering from the University of Michigan and a B.S. in Electrical Engineering from Stanford University.